Skip to main content
Erschienen in: Inflammation Research 5/2017

28.02.2017 | Short Communication

Tissue factor levels in type 2 diabetes mellitus

verfasst von: Prashilla Soma, Albe C. Swanepoel, Janette Bester, Etheresia Pretorius

Erschienen in: Inflammation Research | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Type 2 diabetes mellitus is a pandemic associated with disturbance in haemostasis that could contribute to the development of diabetic vascular disease and accelerated atherosclerosis. In this population, hypercoagulation is prevalent, as well as pathological changes to erythrocytes. This is mainly due to upregulated circulating inflammatory markers.

Materials and methods

Here we looked at tissue factor (TF) levels using ELISA, in a sample of diabetics, with and without cardiovascular complications. Diabetic subjects were recruited from the diabetic clinic at Steve Biko Academic Hospital, Pretoria, South Africa. 20 diabetics with cardiovascular disease and 22 without were enrolled to participate.

Results and conclusion

TF levels were significantly elevated in both diabetic groups when compared to the controls. We suggest that pathologic plasma TF activity, as marker of increased propensity of clot pathology, should be investigated. Agents that might lower TF levels might also possibly lower thrombotic complications.
Literatur
1.
Zurück zum Zitat Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006;55:202–8.CrossRefPubMed Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006;55:202–8.CrossRefPubMed
2.
Zurück zum Zitat Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis. 1996;120:7–14.CrossRefPubMed Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis. 1996;120:7–14.CrossRefPubMed
3.
Zurück zum Zitat Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diabetes Vasc Dis Res. 2010;7:251–9.CrossRef Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diabetes Vasc Dis Res. 2010;7:251–9.CrossRef
4.
Zurück zum Zitat Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diabetes Vasc Dis Res. 2010;7:260–73.CrossRef Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diabetes Vasc Dis Res. 2010;7:260–73.CrossRef
5.
Zurück zum Zitat Virmani R, Roberts WC. Extravasated erythrocytes, iron, and fibrin in atherosclerotic plaques of coronary arteries in fatal coronary heart disease and their relation to luminal thrombus: frequency and significance in 57 necropsy patients and in 2958 five mm segments of 224 major epicardial coronary arteries. Am Heart J. 1983;105:788–97.CrossRefPubMed Virmani R, Roberts WC. Extravasated erythrocytes, iron, and fibrin in atherosclerotic plaques of coronary arteries in fatal coronary heart disease and their relation to luminal thrombus: frequency and significance in 57 necropsy patients and in 2958 five mm segments of 224 major epicardial coronary arteries. Am Heart J. 1983;105:788–97.CrossRefPubMed
6.
Zurück zum Zitat Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J. 2010;74:3–12.CrossRefPubMed Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J. 2010;74:3–12.CrossRefPubMed
8.
Zurück zum Zitat Tatsumi K, Mackman N. Tissue factor and atherothrombosis. J Atheroscler Thromb. 2015;22:543–9.CrossRefPubMed Tatsumi K, Mackman N. Tissue factor and atherothrombosis. J Atheroscler Thromb. 2015;22:543–9.CrossRefPubMed
9.
Zurück zum Zitat Bode MF, Mackman N. Protective and pathological roles of tissue factor in the heart. Hamostaseologie. 2015;35:37–46.CrossRefPubMed Bode MF, Mackman N. Protective and pathological roles of tissue factor in the heart. Hamostaseologie. 2015;35:37–46.CrossRefPubMed
10.
Zurück zum Zitat Cimmino G, D’Amico C, Vaccaro V, D’Anna M, Golino P. The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor? Expert Rev Cardiovasc Ther. 2011;9:517–23.CrossRefPubMed Cimmino G, D’Amico C, Vaccaro V, D’Anna M, Golino P. The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor? Expert Rev Cardiovasc Ther. 2011;9:517–23.CrossRefPubMed
11.
Zurück zum Zitat Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med. 2000;10:139–43.CrossRefPubMed Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med. 2000;10:139–43.CrossRefPubMed
12.
Zurück zum Zitat Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107:973–7.CrossRefPubMed Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107:973–7.CrossRefPubMed
13.
Zurück zum Zitat Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:909154.PubMedPubMedCentral Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:909154.PubMedPubMedCentral
14.
Zurück zum Zitat Storey RF. What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus? Diabetes Vasc Dis Res. 2010;7:249–50.CrossRef Storey RF. What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus? Diabetes Vasc Dis Res. 2010;7:249–50.CrossRef
15.
Zurück zum Zitat Ruszkowska-Ciastek B, Sokup A, Wernik T, Rhone P, Goralczyk K, Bielawski K, et al. Low-grade risk of hypercoagulable state in patients suffering from diabetes mellitus type 2. J Zhejiang Univ Sci B. 2015;16:788–95.CrossRefPubMedPubMedCentral Ruszkowska-Ciastek B, Sokup A, Wernik T, Rhone P, Goralczyk K, Bielawski K, et al. Low-grade risk of hypercoagulable state in patients suffering from diabetes mellitus type 2. J Zhejiang Univ Sci B. 2015;16:788–95.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527–32.CrossRefPubMed Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527–32.CrossRefPubMed
17.
Zurück zum Zitat Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–70.CrossRefPubMedPubMedCentral Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–70.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Olexa P, Olexova M. [Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus]. Vnitr Lek. 2003;49:222–6.PubMed Olexa P, Olexova M. [Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus]. Vnitr Lek. 2003;49:222–6.PubMed
19.
Zurück zum Zitat Fujii S, Goto D, Zaman T, Ishimori N, Watano K, Kaneko T, et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. J Atheroscler Thromb. 1998;5:76–81.CrossRefPubMed Fujii S, Goto D, Zaman T, Ishimori N, Watano K, Kaneko T, et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. J Atheroscler Thromb. 1998;5:76–81.CrossRefPubMed
20.
Zurück zum Zitat Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92:4352–8.CrossRefPubMed Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92:4352–8.CrossRefPubMed
21.
Zurück zum Zitat Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation. 1997;96:2262–71.CrossRefPubMed Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation. 1997;96:2262–71.CrossRefPubMed
22.
Zurück zum Zitat Sommeijer DW, Hansen HR, van Oerle R, Hamulyak K, van Zanten AP, Meesters E, et al. Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with type 2 diabetes. J Thromb Haemost. 2006;4:574–80.CrossRefPubMed Sommeijer DW, Hansen HR, van Oerle R, Hamulyak K, van Zanten AP, Meesters E, et al. Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with type 2 diabetes. J Thromb Haemost. 2006;4:574–80.CrossRefPubMed
23.
Zurück zum Zitat Leurs PB, van Oerle R, Wolffenbuttel BH, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost. 1997;77:472–6.PubMed Leurs PB, van Oerle R, Wolffenbuttel BH, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost. 1997;77:472–6.PubMed
24.
Zurück zum Zitat Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J. 2010;8:7.CrossRefPubMedPubMedCentral Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J. 2010;8:7.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769–71.CrossRefPubMed Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769–71.CrossRefPubMed
26.
Zurück zum Zitat Creasey AA, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med. 2001;29:S126–9.CrossRefPubMed Creasey AA, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med. 2001;29:S126–9.CrossRefPubMed
27.
Zurück zum Zitat El-Hagracy RS, Kamal GM, Sabry IM, Saad AA, Abou El Ezz NF, Nasr HA. Tissue factor, tissue factor pathway inhibitor and factor VII activity in cardiovascular complicated type 2 diabetes mellitus. Oman Med J. 2010;25:173–8.CrossRefPubMedPubMedCentral El-Hagracy RS, Kamal GM, Sabry IM, Saad AA, Abou El Ezz NF, Nasr HA. Tissue factor, tissue factor pathway inhibitor and factor VII activity in cardiovascular complicated type 2 diabetes mellitus. Oman Med J. 2010;25:173–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Tissue factor levels in type 2 diabetes mellitus
verfasst von
Prashilla Soma
Albe C. Swanepoel
Janette Bester
Etheresia Pretorius
Publikationsdatum
28.02.2017
Verlag
Springer International Publishing
Erschienen in
Inflammation Research / Ausgabe 5/2017
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-017-1030-x

Weitere Artikel der Ausgabe 5/2017

Inflammation Research 5/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.